Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Other Accumulated Expenses (2021 - 2024)

Historic Other Accumulated Expenses for Pharmaceuticals (CASI) over the last 4 years, with Q4 2024 value amounting to $3.3 million.

  • Pharmaceuticals' Other Accumulated Expenses rose 669.01% to $3.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.3 million, marking a year-over-year increase of 669.01%. This contributed to the annual value of $3.3 million for FY2024, which is 669.01% up from last year.
  • Per Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $3.3 million for Q4 2024, which was up 669.01% from $3.1 million recorded in Q4 2023.
  • Over the past 5 years, Pharmaceuticals' Other Accumulated Expenses peaked at $3.3 million during Q4 2021, and registered a low of $2.9 million during Q4 2022.
  • Over the past 4 years, Pharmaceuticals' median Other Accumulated Expenses value was $3.2 million (recorded in 2023), while the average stood at $3.2 million.
  • Per our database at Business Quant, Pharmaceuticals' Other Accumulated Expenses crashed by 1273.98% in 2022 and then skyrocketed by 731.71% in 2023.
  • Over the past 4 years, Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $3.3 million in 2021, then fell by 12.74% to $2.9 million in 2022, then increased by 7.32% to $3.1 million in 2023, then grew by 6.69% to $3.3 million in 2024.
  • Its Other Accumulated Expenses stands at $3.3 million for Q4 2024, versus $3.1 million for Q4 2023 and $2.9 million for Q4 2022.